CytoSorbents, Inc.

281 articles with CytoSorbents, Inc.

• CytoSorbents to Present at The MicroCap Rodeo Investor Conference

  10/10/2019

  CytoSorbents Corporation announced that company management will present an overview of the company at The MicroCap Rodeo Investor Conference on Tuesday, October 15, 2019 in Austin, TX and meet with investors in 1x1 meetings throughout the day.

• CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery

  10/4/2019

  CytoSorbents Corporation, a leader in hemoadsorption therapies to treat life-threatening conditions, announced that Dr.

• CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

  10/2/2019

  CytoSorbents Corporation announces positive surgical outcomes in a recent publication entitled, "CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding," in the journal Annals of Thoracic Surgery, ahead of the European Association of Cardio-thoracic Surgery Annual Meeting in Lisbon, Portugal, October 3-5, 2019.

• CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock

  9/25/2019

  CytoSorbents Corporation, a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a new publication entitled, "Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study," in the journal Critical Care.

• First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence

  9/16/2019

  CytoSorbents Corporation announced that Hannover Medical School in Germany will begin the first clinical study called CYTORELEASE, evaluating the use of CytoSorb in treating CRS and inflammation of the brain called CAR-related Encephalopathy Syndrome, following CAR-T cell immunotherapy.

• World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis

  9/13/2019

  CytoSorbents Corporation commemorates World Sepsis Day 2019 through the proud sponsorship of multiple organizations that are promoting sepsis awareness and education, early detection, prompt treatment, and basic and clinical sepsis research.

• CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/9/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Tuesday, September 10, 2019 in New York, NY. Both Dr. Chan and Chief Financial Officer, Kathleen Bloch will meet with investors in 1x1 meetings during the conference on September 9-10, 2019.

• CytoSorbents Highlights Recent Published Studies on CytoSorb

  8/28/2019

  The latter is an involved surgery where blood flow to the body, with the exception of the brain, is completely stopped for up to 45 minutes while the body is rapidly cooled to lower metabolism and oxygen usage. 

• CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica

  8/13/2019

  CytoSorbents is a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world

• CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan

  8/5/2019

  Strengthens the Company's cash position and extends the interest-only period of its $15M debt facility through April 2020, and potentially through October 2020

• CytoSorbents to Report Q2 2019 Operating and Financial Results

  7/30/2019

  CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2019 financial results after the market close on Tuesday, August 6, 2019.

• CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference

  6/18/2019

  CytoSorbents Corporation, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Raymond James Life Sciences and MedTech Conference in New York, NY. Both Dr. Chan and Chief Financial Officer Kathleen Bloch will meet with investors in 1x1 meetings throughout the day.

• CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference

  6/11/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Three Part Advisors 2019 East Coast IDEAS Investor Conference on Thursday, June 13, 2019 in Boston, MA. Dr. Chan will also meet with investors in 1x1 meetings throughout the day.

• CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference

  6/3/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019 in New York, NY.

• CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference

  5/20/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the B. Riley FBR 20th Annual Institutional Investor Conference on Wednesday, May 22, 2019 at 8:00AM PDT in Beverly Hills, CA.

• CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance

  5/7/2019

  CytoSorbents Corporation, a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2019.

• CytoSorbents to Report Q1 2019 Operating and Financial Results

  5/1/2019

  CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2019 financial results after the market close on Tuesday, May 7, 2019.

• CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences

  4/24/2019

  CytoSorbents Corporation shares highlights from the recent 6th International CytoSorb Users' Meeting and the Satellite Symposium at the 39th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium, and the 8th Annual EuroELSO 2019 Conference held recently in Barcelona, Spain.

• CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London

  4/8/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company to European investors, Monday, April 8, 2019, at the H.C. Wainwright Global Life Sciences Conference 2019 in London, England.

• Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor

  3/25/2019

  CytoSorbents Corporation announces that the Medical Device Division of the State of Israel Ministry of Health medical device regulation unit, has granted registration of CytoSorb in Israel, clearing the way to begin selling the device in the country.